secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2023-08-07T23:59:59+00:00
Accession:  0001104659-23-088335
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix Q2 2023 DEXTENZA revenue $15M (+24% YoY), net loss $20.7M, $82.5M credit facility closed
--------------------------------------------------------------------------------

- DEXTENZA net product revenue $15.0M in Q2 2023, up 24% from $12.1M in Q2 2022 and 14% sequentially.
- Total net revenue $15.2M, up 24% YoY; net loss $(20.7)M or $(0.26) per share vs. $(18.8)M loss in Q2 2022.
- Closed $82.5M Barings credit facility; net cash proceeds ~$51.6M after repayment of MidCap debt; cash runway extended into 2025.
- First pivotal trial for OTX-TKI in wet AMD expected to initiate in Q3 2023; HELIOS Phase 1 NPDR trial enrollment completed.
- Full-year 2023 DEXTENZA revenue guidance expected to be upper end of $55M-$60M range; board added Dr. Adrienne Graves in July 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/0001104659-23-088335-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465923088335/tm2322873d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-088335

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer